Brokerages predict that TherapeuticsMD, Inc. (NASDAQ:TXMD) will post earnings of ($0.10) per share for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for TherapeuticsMD’s earnings, with the lowest EPS estimate coming in at ($0.11) and the highest estimate coming in at ($0.10). TherapeuticsMD posted earnings of ($0.19) per share during the same quarter last year, which suggests a positive year over year growth rate of 47.4%. The firm is scheduled to announce its next quarterly earnings report on Thursday, February 18th.
According to Zacks, analysts expect that TherapeuticsMD will report full-year earnings of ($0.62) per share for the current financial year, with EPS estimates ranging from ($0.63) to ($0.57). For the next fiscal year, analysts anticipate that the business will report earnings of ($0.37) per share, with EPS estimates ranging from ($0.54) to ($0.21). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover TherapeuticsMD.
Several research firms have recently weighed in on TXMD. HC Wainwright dropped their target price on shares of TherapeuticsMD from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, January 28th. Zacks Investment Research raised shares of TherapeuticsMD from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a research note on Friday, November 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of TherapeuticsMD in a research note on Tuesday, November 10th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $6.29.
Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. raised its holdings in shares of TherapeuticsMD by 14.6% during the fourth quarter. BlackRock Inc. now owns 21,419,273 shares of the company’s stock valued at $25,918,000 after acquiring an additional 2,727,622 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of TherapeuticsMD by 0.7% during the third quarter. JPMorgan Chase & Co. now owns 13,166,702 shares of the company’s stock valued at $21,199,000 after acquiring an additional 95,922 shares during the period. Morgan Stanley raised its holdings in shares of TherapeuticsMD by 6,296.3% during the fourth quarter. Morgan Stanley now owns 9,278,408 shares of the company’s stock valued at $11,227,000 after acquiring an additional 9,133,350 shares during the period. AXA S.A. raised its holdings in shares of TherapeuticsMD by 7.6% during the third quarter. AXA S.A. now owns 3,388,081 shares of the company’s stock valued at $5,353,000 after acquiring an additional 239,374 shares during the period. Finally, Laurion Capital Management LP acquired a new position in TherapeuticsMD in the 4th quarter valued at approximately $4,006,000. Institutional investors and hedge funds own 52.56% of the company’s stock.
TherapeuticsMD, Inc operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17Ã-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system.
Recommended Story: What is meant by a buy rating?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.